Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Emile Andari"'
Autor:
Rita Medlej, Mohamed M. El-Zaheri, Paola Atallah, Charles Saab, Kamal Hirbli, Omar M. Abu-Hijleh, Nadim Jarrah, Fares Haddad, Emile Andari, Hiba Hajar
Publikováno v:
Journal of Diabetes Mellitus. 10:73-87
Introduction: Type 2 Diabetes Mellitus (T2DM) has witnessed a rise in its prevalence worldwide and in the Middle East region. The overall burden associated with the disease is well characterized, but little is known about patient satisfaction in the
Autor:
Selim Jambart, Emile Andari, Paola Atallah, Harry Howlett, Charles Saab, Akram Echtay, Murad Al-Naqshbandi, Sami T. Azar
Publikováno v:
Science progress. 104(3)
Given that the complications of type 2 diabetes can start at an early stage, early detection and appropriate management of prediabetes are essential. We aimed to develop an expert opinion on prediabetes in Lebanon to pave the way for national guideli
Autor:
Rita Nemr, Samir Arnaout, Antoine Sarkis, Mounzer Saleh, Emile Andari, Elie Chammas, Sami T. Azar, Selim Jambart
Publikováno v:
Current diabetes reviews. 16(8)
Background: Cardiovascular disease (CVD), the main macro vascular complication of type 2 diabetes (T2D), increases the risk of death significantly in patients with T2D. Introduction: Most of the patients with T2D do not have obvious CVD symptoms. Due
Publikováno v:
Ethnicitydisease. 27(1)
Objective: To evaluate the effectiveness and safety of insulin detemir treatment as add-on therapy in a real-world setting of Lebanese insulin naïve persons, with type 2 diabetes poorly controlled on oral antidiabetic drugs (OADs).Methods: Our stu
Autor:
Mohammad I. Hasan, Levent Sandalci, Saleem Qureshi, Bracha Dagan, Asude Ademogulları, Paola Atallah, M. Omar Abu-Hijleh, Nidal Al Khatib, Jihad Haddad, Anat Tsur, Jamal Zafar, Akram Echtay, Emile Andari
Publikováno v:
Diabetes Therapy
Introduction This study aimed at determining the clinical safety and efficacy of insulin detemir (IDet) in combination with oral anti-diabetic drugs (OADs) in type 2 diabetes (T2D) patients from four Near East Countries (Israel, Jordan, Pakistan and